- Home
- QTTB vs IBIO Comparison
QTTB vs IBIO Comparison
Compare QTTB & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- IBIO
- Stock Information
- Founded
- QTTB 2015
- IBIO 2008
- Country
- QTTB United States
- IBIO United States
- Employees
- QTTB N/A
- IBIO N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- QTTB Health Care
- IBIO Health Care
- Exchange
- QTTB Nasdaq
- IBIO Nasdaq
- Market Cap
- QTTB 27.7M
- IBIO 24.3M
- IPO Year
- QTTB N/A
- IBIO N/A
- Fundamental
- Price
- QTTB $1.86
- IBIO $5.55
- Analyst Decision
- QTTB Hold
- IBIO Strong Buy
- Analyst Count
- QTTB 8
- IBIO 3
- Target Price
- QTTB $24.00
- IBIO $4.87
- AVG Volume (30 Days)
- QTTB 242.9K
- IBIO 843.9K
- Earning Date
- QTTB 03-11-2025
- IBIO 02-10-2025
- Dividend Yield
- QTTB N/A
- IBIO N/A
- EPS Growth
- QTTB N/A
- IBIO N/A
- EPS
- QTTB N/A
- IBIO N/A
- Revenue
- QTTB N/A
- IBIO $375,000.00
- Revenue This Year
- QTTB N/A
- IBIO $36.00
- Revenue Next Year
- QTTB N/A
- IBIO $33.33
- P/E Ratio
- QTTB N/A
- IBIO N/A
- Revenue Growth
- QTTB N/A
- IBIO 650.00
- 52 Week Low
- QTTB $1.85
- IBIO $1.05
- 52 Week High
- QTTB $53.79
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- QTTB 23.73
- IBIO 62.10
- Support Level
- QTTB $2.04
- IBIO $5.23
- Resistance Level
- QTTB $2.43
- IBIO $5.85
- Average True Range (ATR)
- QTTB 0.20
- IBIO 0.77
- MACD
- QTTB 0.11
- IBIO 0.04
- Stochastic Oscillator
- QTTB 1.82
- IBIO 62.15
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.